News & Events

OBN Annual Awards Dinner 2013: College Hill Congratulates Three of Its Clients on Their Wins

OBN Annual Awards Dinner 2013: College Hill Congratulates Three of Its Clients on Their Wins

03 October 2013, London & Manchester, UK: College Hill Life Sciences is pleased to congratulate three of its clients on their wins at the UK’s OBN Annual Awards Dinner 2013.  The awards seek to highlight the many achievements and major success stories of the UK’s bioscience sector in raising funds, executing deals and supporting innovation.

Autifony Therapeutics was awarded Best Emerging Biotech for its top up Series A round of £5.5m which brings the funds raised up to £15.5m, as well as a £2.75m collaboration announced in 2013.

By using pioneering science and targeting specific ion channels which regulate neuronal activity within the auditory system, Autifony is developing new drugs to treat hearing disorders.

Best Biotech Fundraiser was awarded to Karus Therapeutics for its raising of £5m as the first tranche of a Series B investment in September 2012 from top tier investors SV Life Sciences (UK and International), New Leaf Venture Partners (US), Novo A/S (Denmark), IP Group (UK), Esperante Ventures (Netherlands) and a number of Angel investors.  Karus is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer.  The award recognises the progression the company has made in securing this fundraising from this syndicate.

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, was awarded Best Medtech Dealmaker, which recognises innovative and entrepreneurial deals.  Backed by £1.16m from the TSB, OGT collaboratively developed a panel of 58 cancer-associated genes for diagnostic purposes with Birmingham and Salisbury NHS Regional Genetics Laboratories.

College Hill clients e-Therapeutics and Atopix were also shortlisted for Best Biotech Fundraiser and Best Emerging Biotech respectively.

Dr Jon Rees, OBN’s CEO, said “This year’s awards highlight the vibrancy and variety of the broader life sciences sector in the UK and, despite tough financing conditions, the progress companies have been able to make and the tangible successes delivered. As OBN expands its sphere of influence across the UK, we were delighted to welcome a larger number of entrepreneurs from across the UK to the Awards Dinner than any previous year.”

For the full list of finalists and winners, please click here.

OBN Awards

For further information:
Sue Charles
Managing Partner, Life Sciences
+44 (0)20 7457 2020

back to news